UK Continuous Glucose Monitoring Devices Market (2025 - 2033)

Market Size & Trends

The UK continuous glucose monitoring devices market size was valued at USD 532.2 million in 2024 and is expected to reach USD 1,952.8 million by 2033, growing at a CAGR of 15.5% from 2025 to 2033. The UK continuous glucose monitoring (CGM) devices market is growing due to rising diabetes prevalence, increasing demand for real-time glucose monitoring, and NHS support for CGM adoption, especially among insulin-treated Type 1 and Type 2 patients. Technological advancements, such as long-lasting sensors, smartphone integration, and non-invasive devices, further drive market penetration. Companies like Abbott, Dexcom, and newcomers like Yuwell are making CGMs more accessible and affordable. Government-backed initiatives focusing on prevention, remission, and personalized diabetes management also contribute to market expansion.

New research from the University of Leicester’s Diabetes Research Centre highlights the significant benefits of continuous glucose monitoring (CGM) for individuals with Type 2 diabetes in the UK, while also revealing barriers to its widespread adoption. CGM devices, usually worn on the arm, allow real-time tracking of blood glucose levels, enabling quicker, more accurate treatment decisions. The study, published in Diabetic Medicine, confirms that CGMs help reduce episodes of high and low blood sugar, support lifestyle improvements, and provide doctors with actionable data. However, it also identifies a lack of adequate training among healthcare professionals and resistance to new workflows as major hindrances.

More than 3.6 million people in the UK are living with diabetes, with about 90% diagnosed with Type 2. This chronic condition, though manageable through medication and lifestyle changes, remains a leading cause of preventable complications such as vision loss, kidney failure, and cardiovascular disease. Professor Samuel Seidu, lead author of the study and vice chair for Research at Primary Care Diabetes Europe, emphasized:

In parallel, the UK’s CGM market is witnessing innovation and investment. For instance, UK-based startup Sava raised USD 8 million to develop a next-generation CGM using microneedles. These smaller sensors aim to be less invasive and more cost-effective than traditional systems, making CGMs more appealing to a broader user base. Unlike current devices that use a single 6mm needle, Sava’s technology uses several 1mm microneedles, offering a more comfortable experience and the potential to monitor additional biomarkers beyond glucose.

Sava’s founders believe the CGM market is expanding beyond diabetes care, with interest growing among health-conscious consumers and healthcare providers alike. They foresee the ability to monitor other molecules such as ketones, urea, or proteins, which could benefit sports performance, nutrition, and general wellness monitoring. The startup has also received approval from the UK’s MHRA to begin clinical trials and is investing in scaling up production to bring its first product to market within two years.

The UK Continuous Glucose Monitoring (CGM) devices market is expanding rapidly, driven by rising diabetes prevalence, supportive NHS initiatives, and evolving consumer preferences. Major players like Abbott, Dexcom, and Medtronic dominate with a strong presence across both Type-1 and Type-2 diabetes segments. Companies such as Nemaura Medical and GlucoRx focus on affordability and accessibility, particularly for Type-2 users. Emerging firms like GlySens and Vively Health Pty Ltd are contributing innovative, patient-friendly technologies. The market reflects growing diversification in product formats, wearability, and digital integration, creating a dynamic landscape for both established manufacturers and new entrants focused on personalized and preventive care. The table includes all major players actively contributing to the UK continuous glucose monitoring (CGM) market.

The UK CGM devices market, especially in the context of price-conscious consumer adoption, is shaped by a comparative cost-focused strategy between the two leading players, Abbott (FreeStyle Libre) and Dexcom (G6/G7). Their distinct pricing and accessibility models significantly influence their competitive positioning and overall market penetration strategies.

Go-To Strategy: UK CGM Devices Market – Abbott vs Dexcom

Strategic Insights:

Abbott’s Advantage: Lower ongoing and upfront costs, optional reader, widespread NHS support, ideal for scaling among Type-2 and insulin-treated patients.

Dexcom’s Positioning: Superior real-time features and alerts, but higher initial costs limit mass-market appeal unless covered by NHS; ideal for Type-1 intensive management.

Understanding the distinction between OTC and prescription-based CGM devices is crucial for evaluating growth opportunities in the UK market. OTC CGMs expand access to individuals with Type-2 diabetes or those at risk, especially in underserved or cost-sensitive segments. These devices allow self-monitoring and lifestyle-driven diabetes management without clinical gatekeeping. Meanwhile, prescription-based CGMs supported by the NHS serve a more medically intensive population, particularly Type-1 patients. Together, both categories enable broader market penetration by meeting varied user needs. As awareness grows and policies evolve to support CGM use, this dual-channel approach will be instrumental in driving widespread adoption and improving diabetes outcomes.

Comparison: OTC Products vs Prescription CGM Devices in the UK

The global adoption of continuous glucose monitoring (CGM) devices has surpassed 7 million users, demonstrating a significant impact on diabetes management worldwide, according to Abbott in May 2025. In the UK, particularly England, over 200,000 patients have benefited from CGMs through the NHS, representing a third increase in uptake within months of the 2022 rollout. Around 80% of people with Type 1 diabetes now have access to CGM technology. This rapid expansion is driven by NHS initiatives to improve diabetes care, lower long-term healthcare costs, and enhance patient quality of life. The transition from finger-prick tests to real-time monitoring has transformed diabetes self-management and outcomes across the region.

Market Concentration & Characteristics

The industry is moderately concentrated, with key players like Abbott and Dexcom dominating the market through strong brand recognition, NHS partnerships, and innovative technology. Abbott holds a significant share, driven by the affordability and accessibility of its FreeStyle Libre system. Dexcom leads in premium real-time CGM solutions, particularly among Type 1 diabetes users. The industry is characterized by rapid technological advancements, growing NHS support, and increasing adoption among Type 2 diabetics. Emerging companies such as GlucoRx and Nemaura Medical are also entering the market with cost-effective and non-invasive solutions, fostering competitive dynamics.

The industry is witnessing a surge in innovation, with Spirit Health introducing its latest product, CareSens Air, to the market. This new continuous glucose monitor will be available on the Drug Tariff starting February 2025, offering a more affordable and user-friendly alternative for people managing diabetes. The CareSens Air is a 15-day wear device that delivers real-time glucose readings directly to a user’s smartphone. With its sleek design and all-in-one applicator, it simplifies the glucose monitoring process while maintaining accuracy and efficiency.

The introduction of CareSens Air expands options for both patients and healthcare professionals, enhancing accessibility and potentially lowering NHS expenses. Its companion app enriches user engagement with functions like customized alerts, glucose trend analysis, and remote access for clinicians and caregivers. Supporting this, Spirit Health’s Chief Executive remarked,

“We’re thrilled to bring CareSens Air to the Drug Tariff this February. This innovative device bridges critical gaps in diabetes care by offering a reliable, user-friendly tool that enhances patient outcomes while being mindful of healthcare budgets helping us make healthcare simple and more accessible for all.”

Two global medical device giants have joined forces to tackle Type II diabetes in the UK, aiming to reduce NHS costs and curb the disease's alarming growth. In May 2025, UK-based Urathon Europe Ltd secured exclusive distribution rights for the Yuwell Anytime CGM, developed by Chinese manufacturer Yuwell. This strategic partnership marks a significant milestone in M&A activity within the UK CGM industry, introducing a next-generation, cost-effective device targeting the nation’s Type II diabetes crisis.

With the world-first rechargeable transmitter lasting two years, Yuwell Anytime CGM offers over 35% annual cost savings compared to existing systems. It enhances early monitoring for both Type II diabetics and prediabetic individuals, supporting prevention and potential remission. Given that 90% of UK diabetes cases are Type II and with a 40% rise in under-40 cases from 2017–2023, the device addresses a critical public health need.

This collaboration supports a national CGM campaign, working with Leeds, Brunel, and UCL Universities, backed by the NIHR, to expand grassroots access. With wide-scale NHS integration, the Yuwell Anytime CGM promises to save billions annually while transforming care delivery and patient outcomes across the UK.

The industry is significantly influenced by regulatory measures aimed at ensuring patient safety and device reliability. The Medicines and Healthcare products Regulatory Agency (MHRA) actively encourages users to report safety concerns through the Yellow Card scheme. Despite millions relying on CGM devices, underreporting remains a concern. To address this, the MHRA has introduced clearer guidance to improve the quality and frequency of reports. These efforts aim to enhance post-market surveillance, identify potential risks early, and implement necessary regulatory actions. Strong backing from NHS officials and diabetes organizations reinforces the importance of maintaining high safety standards.

In the UK, traditional finger-prick blood glucose meters remain the primary substitute for CGM systems, offering a low-cost and widely accessible alternative. Flash monitoring systems like Abbott’s FreeStyle Libre serve as a middle-ground option, providing periodic glucose readings without requiring continuous wear. Insulin pumps with integrated glucose sensing offer a semi-automated substitute, often used by Type 1 patients seeking tighter control. Additionally, emerging non-invasive glucose devices-such as optical sensors-are gaining interest, although they’re not yet mainstream. Finally, smartphone health apps combined with periodic lab tests can partially replace CGMs, especially where cost or access is a concern.

The industry is witnessing notable growth with Spirit Health’s announcement to launch its CareSens Air CGM in February 2025. This user-friendly, 15-day wearable sensor sends glucose readings directly to a smartphone every five minutes. Designed for simplicity and affordability, it features an ergonomic, all-in-one applicator that ensures painless attachment and minimal discomfort. The integrated mobile app offers real-time trend visualization, personalized alerts, and lifelog tracking for effective glucose management. It also supports remote monitoring by caregivers and healthcare professionals, enhancing data-driven care. This regional launch reinforces Spirit Health’s commitment to accessible and connected diabetes solutions.

Product Insights

The standalone CGM systems segment dominated the market and accounted for the largest revenue share in 2024. These devices function independently without needing integration with insulin pumps, making them accessible to a wider diabetic population, especially those with Type 2 diabetes. Their increasing availability through the NHS, pharmacies, and online platforms has accelerated adoption. Additionally, government support for digital diabetes management, growing awareness, and clinical preference for non-invasive monitoring options contributed to their dominance. Affordability, innovation, and improved accuracy further reinforced their strong position in the UK CGM market.

The integrated CGM-insulin pump systems segment is expected to witness the fastest growth in the UK CGM devices market during the forecast period. This growth is driven by rising adoption of automated insulin delivery systems, increased prevalence of Type 1 diabetes, and growing preference for closed-loop solutions. The NHS’s expanding support for hybrid closed-loop therapies and favorable reimbursement policies has further encouraged usage. These systems offer better glycemic control, reduced hypoglycemia risk, and improved patient convenience. Technological advancements, such as Bluetooth connectivity and AI-driven analytics, also contribute to demand. As a result, this segment is poised for significant market expansion.

Connectivity Insights

The Bluetooth segment dominated the UK CGM devices market in 2024, capturing the largest revenue share due to its widespread integration in modern glucose monitoring systems. Bluetooth-enabled CGMs allow seamless real-time data transmission to smartphones and wearable devices, improving patient engagement and facilitating remote monitoring by healthcare providers. This wireless connectivity supports better diabetes management through timely alerts and data-driven insights. Increased adoption of digital health platforms, rising awareness of connected care, and compatibility with telemedicine services further fueled this segment’s growth. Additionally, the reliability, low energy consumption, and user convenience of Bluetooth technology solidified its leading market position.

The NFC (Near Field Communication) segment in the UK CGM devices market is projected to witness the fastest growth during the forecast period due to its simplicity, affordability, and growing acceptance among patients and healthcare providers. NFC technology allows users to scan their CGM sensors with smartphones to instantly access glucose data without requiring continuous connectivity. This low-power, tap-and-read method is particularly appealing for Type 2 diabetes patients and elderly users seeking user-friendly options. Additionally, the expansion of NHS digital health initiatives and increased penetration of NFC-enabled smartphones contribute to rising adoption, positioning NFC as a cost-effective solution for routine diabetes care.

Indication Insights

The type 1 diabetes segment dominated the UK CGM devices market in 2024, accounting for the largest revenue share. This dominance is attributed to the essential need for continuous glucose monitoring among type 1 diabetes patients who rely on insulin therapy. According to The British Diabetic Association, approximately 8% of people with diabetes in the UK have type 1 diabetes, necessitating real-time glucose tracking to manage blood sugar fluctuations. Government support through NHS reimbursement, increased awareness, and improved access to CGM devices have further fueled adoption. Technological advancements and patient preference for minimally invasive solutions also supported market leadership.

The type 2 diabetes segment is projected to grow at the fastest rate in the UK CGM devices market during the forecast period. According to The British Diabetic Association, around 90% of people with diabetes in the UK have type 2 diabetes, highlighting a significant target population. As awareness grows about the benefits of continuous glucose monitoring for improved glycemic control and complication prevention, CGM adoption among type 2 patients is accelerating. Government initiatives, NHS pilot programs, and the availability of cost-effective, user-friendly CGM devices are further driving this growth, especially among patients seeking proactive, personalized diabetes management solutions.

End Use Insights

The pharmacies segment dominated the UK CGM devices market in 2024, accounting for the largest revenue share due to their widespread accessibility and role in dispensing prescription-free CGM systems like the FreeStyle Libre. Pharmacies, both independent and chain-based, have become essential distribution points for CGMs, supported by NHS partnerships and growing patient demand. Their ability to offer professional guidance, convenient access, and support services has increased trust and usage among patients. The integration of CGM devices into pharmacy-led diabetes programs and expanding health services has further reinforced their dominance in the market, especially for both type 1 and type 2 patients.

The e-commerce segment is expected to grow at the fastest rate in the UK CGM devices market due to rising digital adoption, convenience of home delivery, and increasing consumer preference for online health purchases. Platforms like Amazon, Boots, and manufacturer websites offer a wide range of CGM devices, often with competitive pricing and subscription models. The COVID-19 pandemic accelerated online health shopping trends, which continue to influence purchasing behavior. Additionally, tech-savvy diabetic patients, especially younger users, prefer digital channels for device comparison and reviews. These factors are driving strong growth and transforming e-commerce into a key distribution channel for CGMs.

Key UK CGM Device Companies Insights

Key players operating in the UK CGM device market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In May 2025, Yuwell launched the Anytime CGM in the UK, featuring a world-first rechargeable transmitter lasting two years. Designed for Type 2 diabetes, it cuts costs by over 35% and aims to revolutionize access. Backed by UK universities, it supports prevention, remission, and NHS cost reduction.

• In May 2024, Dexcom launched the Dexcom ONE+ CGM in the UK. Featuring the latest G7 sensor, it offers real-time glucose monitoring with smartphone and smartwatch compatibility. Designed for insulin-treated Type 1 and Type 2 diabetes, ONE+ enhances ease of use and tracks lifestyle-related glucose impacts.

• In December 2021, Nemaura Medical completed its first shipment of sugarBEAT CGM devices to UK licensee MySugarWatch. Targeting Type 2 diabetes, the launch includes a subscription-based coaching service. This milestone marks Nemaura’s first revenue and paves the way for broader EU expansion starting in 2022.

UK Continuous Glucose Monitoring Devices Market